PLEASANTON, Calif. - Movano Health (NASDAQ:MOVE) has submitted a comprehensive response to the FDA, marking the final phase of its 510(k) application process for the EvieMED Ring, the company reported today. The wearable device, which features pulse oximetry, aims to offer a range of wellness metrics and medical device functionality.
John Mastrototaro, President and CEO of Movano Health, expressed confidence in the EvieMED Ring's potential and the company's commitment to the 510(k) review process. "Our team has worked diligently to provide a thorough response to the Agency's questions," said Mastrototaro. "We look forward to the successful completion of the 510(k) review process and continue to focus on the game-changing opportunities that we believe EvieMED could unlock for our partners in remote patient monitoring and clinical trials."
Movano Health, founded in 2018, is known for developing healthcare solutions that bring medical-grade data to wearable technology. The EvieMED Ring is part of Movano's efforts to provide devices that deliver trusted data to both consumers and enterprises, enabling proactive health management.
The company's forward-looking statements indicate plans for commercial launches and expectations for FDA clearance decisions. However, these statements are based on current assumptions and subject to risks and uncertainties, as detailed in the company's filings with the Securities and Exchange Commission.
This news is based on a press release statement and does not include any endorsement of the claims. Movano Health's progress with the FDA is a significant step in the wearable health technology market, but the outcome of the FDA's decision remains to be seen.
In other recent news, healthcare solutions company Movano Health has been actively investigating potential stock manipulation following a shareholder-approved reverse stock split. The company has also made significant progress with the FDA's review process for its EvieMED Ring, a device designed for remote patient monitoring and clinical trials. Despite reporting an operating loss of $6.4 million in the second quarter, Movano Health shipped 1,837 Evie Rings and established collaborations with two global pharmaceutical companies and a large payer, indicating potential commercial opportunities. Furthermore, the company has completed a blood pressure clinical study and is redesigning the device for improved sensor placement. These recent developments reflect Movano Health's ongoing commitment to its operations and market expansion. In addition, Movano Health announced a 1-for-15 reverse stock split to maintain its Nasdaq listing, reducing the number of outstanding shares from about 99.5 million to approximately 6.6 million. Lastly, the company is in the final phase of the FDA's 510(k) clearance process, particularly for the device's pulse oximetry feature.
InvestingPro Insights
As Movano Health (NASDAQ:MOVE) advances its FDA application for the EvieMED Ring, investors should consider some key financial metrics and insights from InvestingPro. The company's market capitalization stands at a modest $24.74 million, reflecting its early-stage status in the competitive wearable health technology market.
InvestingPro data reveals that Movano's revenue for the last twelve months as of Q2 2023 was $0.85 million, indicating the company is still in its growth phase. This aligns with the company's focus on developing and seeking approval for its innovative EvieMED Ring.
Two relevant InvestingPro Tips highlight potential challenges for Movano Health:
1. The company is quickly burning through cash, which is not uncommon for early-stage medical technology firms but warrants attention from investors.
2. Analysts do not anticipate the company will be profitable this year, underscoring the importance of the EvieMED Ring's potential success for Movano's financial future.
These insights suggest that while Movano Health is making progress with its FDA application, the company faces financial hurdles typical of emerging medical technology firms. The outcome of the FDA's decision on the EvieMED Ring could significantly impact the company's trajectory.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide deeper insights into Movano Health's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.